FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
This article was originally published in The Tan Sheet
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8
You may also be interested in...
FDA's Center for Drug Evaluation and Research will crack down on manufacturers that attempt to "farm out responsibility," firms that fail to meet reporting requirements and the general "criminalization of our drug supply," said Deb Autor, director of the center's compliance office
FDA's Office of Pediatric Therapeutics expects to develop by 2012 a manual to guide agency staff on the use of extrapolation when assessing pediatric products and their development programs
FDA's initiative to remove unapproved new drugs from the market extends to topical ibuprofen products as the agency warns eight firms about lotions containing the common nonprescription ingredient